VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
Study validates proprietary technology that could transform flu vaccine production
“VaxInnate’s M2e universal flu vaccine candidate has passed a critical initial test,” said David Taylor, MD, Chief Medical Officer. “We’re encouraged by these data, which demonstrate that the vaccine is safe and elicits potent immune responses at doses below a microgram of vaccine antigen, and does so without the use of conventional adjuvants.”
The multicenter, double-blind, randomized, placebo-controlled Phase I study was designed to assess the safety and immunogenicity of four doses of the vaccine candidate. The vaccine candidate is comprised of the ectodomain of the viral M2 protein (M2e) fused to the bacterial protein flagellin.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.